CHEK
Check-Cap Ltd.
Medical - Diagnostics & Research
Market Cap$12M
5Y Perf.-82.6%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CHEK vs CLOV
Revenue, margins, valuation, and 5-year total return — side by side.
CLOV
Clover Health Investments, Corp.
Medical - Healthcare Plans
Market Cap$1.37B
5Y Perf.-79.0%
CHEK vs CLOV — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CHEK | CLOV |
|---|---|---|
| Industry | Medical - Diagnostics & Research | Medical - Healthcare Plans |
| Market Cap | $12M | $1.37B |
| Revenue (TTM) | $0.00 | $2.21B |
| Net Income (TTM) | $-25M | $-57M |
| Gross Margin | — | 42.5% |
| Operating Margin | — | -2.6% |
| Forward P/E | — | 62.6x |
| Total Debt | $136K | $0.00 |
| Cash & Equiv. | — | $78M |
CHEK vs CLOV — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CHEK
CLOV
| Stock | Jun 20 | Jan 26 | Return |
|---|---|---|---|
| Check-Cap Ltd. (CHEK) | 100 | 17.4 | -82.6% |
| Clover Health Inves… (CLOV) | 100 | 21.0 | -79.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CHEK vs CLOV
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CHEK leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Clover Health Investments, Corp. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. As sector peers, any of these can serve as alternatives in the same allocation.
CHEK
Check-Cap Ltd.
The Income Pick
CHEK carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.67
- EPS growth -43.3%
- Lower volatility, beta 0.67, current ratio 0.15x
Best for: income & stability and growth exposure
CLOV
Clover Health Investments, Corp.
The Insurance Pick
CLOV is the clearest fit if your priority is long-term compounding.
- -73.7% 10Y total return vs CHEK's -99.7%
- 40.3% revenue growth vs CHEK's -48.5%
- -9.6% ROA vs CHEK's -66.7%, ROIC -34.0% vs -287.7%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CLOV | 40.3% revenue growth vs CHEK's -48.5% |
| Quality / Margins | CHEK | 212.2% margin vs CLOV's -2.6% |
| Stability / Safety | CHEK | Beta 0.67 vs CLOV's 1.22 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CHEK | +101.9% vs CLOV's -20.0% |
| Efficiency (ROA) | CLOV | -9.6% ROA vs CHEK's -66.7%, ROIC -34.0% vs -287.7% |
CHEK vs CLOV — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
CHEK vs CLOV — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCLOVLAGGINGCHEK
CHEKCheck-Cap Ltd.
0leads
CLOVClover Health Investm…
3leads
6 Total Categories
CATEGORYLEADERvs CHEKMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
—
—
Valuation MetricsMultiples, price ratios, and targets
CLOV1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CLOV6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
CLOV4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
Insufficient data to determine a leader in this category.
Income & Cash Flow (Last 12 Months)
CLOV and CHEK operate at a comparable scale, with $2.2B and $0 in trailing revenue.
| Metric | CHEKCheck-Cap Ltd. | CLOVClover Health Inv… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $2.2B |
| EBITDAEarnings before interest/tax | -$26M | -$55M |
| Net IncomeAfter-tax profit | -$25M | -$57M |
| Free Cash FlowCash after capex | -$8,004 | $55M |
| Gross MarginGross profit ÷ Revenue | — | +42.5% |
| Operating MarginEBIT ÷ Revenue | — | -2.6% |
| Net MarginNet income ÷ Revenue | — | -2.6% |
| FCF MarginFCF ÷ Revenue | — | +2.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +62.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -155.6% | — |
Insufficient data to determine a leader in this category.
Valuation Metrics
CLOV leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | CHEKCheck-Cap Ltd. | CLOVClover Health Inv… |
|---|---|---|
| Market CapShares × price | $12M | $1.4B |
| Enterprise ValueMkt cap + debt − cash | $12M | $1.3B |
| Trailing P/EPrice ÷ TTM EPS | -0.48x | -15.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 62.62x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.71x |
| Price / BookPrice ÷ Book value/share | — | 4.49x |
| Price / FCFMarket cap ÷ FCF | — | — |
CLOV leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
CLOV leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
CLOV delivers a -17.1% return on equity — every $100 of shareholder capital generates $-17 in annual profit, vs $-2 for CHEK.
| Metric | CHEKCheck-Cap Ltd. | CLOVClover Health Inv… |
|---|---|---|
| ROE (TTM)Return on equity | -2.3% | -17.1% |
| ROA (TTM)Return on assets | -66.7% | -9.6% |
| ROICReturn on invested capital | -2.9% | -34.0% |
| ROCEReturn on capital employed | -2.3% | -24.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 |
| Debt / EquityFinancial leverage | — | — |
| Net DebtTotal debt minus cash | $136,000 | -$78M |
| Cash & Equiv.Liquid assets | — | $78M |
| Total DebtShort + long-term debt | $136,000 | $0 |
| Interest CoverageEBIT ÷ Interest expense | -2883.22x | — |
CLOV leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
CLOV leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CLOV five years ago would be worth $3,256 today (with dividends reinvested), compared to $707 for CHEK. Over the past 12 months, CHEK leads with a +101.9% total return vs CLOV's -20.0%. The 3-year compound annual growth rate (CAGR) favors CLOV at 45.1% vs CHEK's 14.1% — a key indicator of consistent wealth creation.
| Metric | CHEKCheck-Cap Ltd. | CLOVClover Health Inv… |
|---|---|---|
| YTD ReturnYear-to-date | +21.3% | +11.2% |
| 1-Year ReturnPast 12 months | +101.9% | -20.0% |
| 3-Year ReturnCumulative with dividends | +48.6% | +205.7% |
| 5-Year ReturnCumulative with dividends | -92.9% | -67.4% |
| 10-Year ReturnCumulative with dividends | -99.7% | -73.7% |
| CAGR (3Y)Annualised 3-year return | +14.1% | +45.1% |
CLOV leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CHEK and CLOV each lead in 1 of 2 comparable metrics.
Risk & Volatility
CHEK is the less volatile stock with a 0.67 beta — it tends to amplify market swings less than CLOV's 1.22 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CLOV currently trades 68.4% from its 52-week high vs CHEK's 53.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CHEKCheck-Cap Ltd. | CLOVClover Health Inv… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.67x | 1.22x |
| 52-Week HighHighest price in past year | $3.92 | $3.92 |
| 52-Week LowLowest price in past year | $0.59 | $1.58 |
| % of 52W HighCurrent price vs 52-week peak | +53.1% | +68.4% |
| RSI (14)Momentum oscillator 0–100 | 58.5 | 67.0 |
| Avg Volume (50D)Average daily shares traded | 2.5M | 5.6M |
Evenly matched — CHEK and CLOV each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | CHEKCheck-Cap Ltd. | CLOVClover Health Inv… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold |
| Price TargetConsensus 12-month target | — | $3.33 |
| # AnalystsCovering analysts | — | 9 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +4.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CLOV leads in 3 of 6 categories — strongest in Valuation Metrics and Profitability & Efficiency. 1 category is tied.
Best OverallClover Health Investments, … (CLOV)Leads 3 of 6 categories
Loading custom metrics...
CHEK vs CLOV: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CHEK or CLOV a better buy right now?
Analysts rate Clover Health Investments, Corp.
(CLOV) a "Hold" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CHEK or CLOV?
Over the past 5 years, Clover Health Investments, Corp.
(CLOV) delivered a total return of -67. 4%, compared to -92. 9% for Check-Cap Ltd. (CHEK). Over 10 years, the gap is even starker: CLOV returned -73. 7% versus CHEK's -99. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CHEK or CLOV?
By beta (market sensitivity over 5 years), Check-Cap Ltd.
(CHEK) is the lower-risk stock at 0. 67β versus Clover Health Investments, Corp. 's 1. 22β — meaning CLOV is approximately 82% more volatile than CHEK relative to the S&P 500.
04Which is growing faster — CHEK or CLOV?
On earnings-per-share growth, the picture is similar: Check-Cap Ltd.
grew EPS -43. 3% year-over-year, compared to -93. 6% for Clover Health Investments, Corp.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CHEK or CLOV?
Check-Cap Ltd.
(CHEK) is the more profitable company, earning 0. 0% net margin versus -4. 4% for Clover Health Investments, Corp. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CHEK leads at 0. 0% versus -4. 4% for CLOV. At the gross margin level — before operating expenses — CLOV leads at 18. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CHEK or CLOV?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CHEK or CLOV better for a retirement portfolio?
For long-horizon retirement investors, Check-Cap Ltd.
(CHEK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 67)). Both have compounded well over 10 years (CHEK: -99. 7%, CLOV: -73. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CHEK and CLOV?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: CHEK is a small-cap quality compounder stock; CLOV is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.